Active, not recruiting
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
|2||Active, not recruiting||
Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations
† Study has passed its completion date and status has not been verified in more than two years.